Day: October 23, 2023

FORT LAUDERDALE, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) — Golden Grail Beverages (OTC: GOGY) is proud to announce its partnership with Imperial Beverages, Michigan’s premier beer, wine, and spirits wholesaler, to distribute Sway Energy drinks. Golden Grail Beverages announced in August that Imperial Beverages started distributing Spider Energy drinks; this collaboration expands the presence of Sway Energy drinks within Michigan. Established in 1933, Imperial Beverages has solidified its reputation as a pivotal player in Michigan’s beverage distribution landscape. Their dedication to serving every county, combined with an extensive portfolio of over 6,000 SKUs, positions them as a top choice for many brands. Sway Energy drinks stand out in the saturated energy drink market, setting a new standard for clean energy beverages....

CEDARHURST, N.Y., Oct. 23, 2023 (GLOBE NEWSWIRE) — Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 1,800 properties leased primarily to the United States Postal Service (the “USPS”), ranging from last-mile post offices to larger industrial facilities, announced today that its board of directors has approved a quarterly dividend on the Company’s Class A common stock in the amount of $0.2375 per share. This represents a 1.1% increase from the third quarter 2022 dividend. The dividend will be payable on November 30, 2023 to stockholders of record as of the close of business on November 1, 2023. About Postal Realty Trust, Inc. Postal Realty Trust, Inc. is an internally managed real estate investment trust that owns and manages over 1,800 postal properties...

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the European Society for Medical Oncology Congress (ESMO) 2023. The multi-center Phase 1/2 clinical trial is a first-in-human, open-label, dose escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of SNS-101 as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo® in patients with advanced solid tumors. To date, four...

– 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients – 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients – Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data, as of a July 31, 2023 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) cancer presented by Principal Investigator, Dr. Alison Schram* of Memorial Sloan Kettering...

Management to Host Third Quarter 2023 Conference Call on Thursday, November 2, 2023 LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today preliminary financial results for the third quarter of 2023. The Company expects third quarter 2023 revenue to be between $2.6 to $2.8 million, representing an increase of between 60% to 70% from second quarter 2023 revenue of $1.63 million. The launch of the iSpecimen’s next-day quote program in the third quarter of 2023 is a key driver of the Company’s higher financial performance for the third quarter of 2023, as it accelerates the biospecimen transaction process, leading...

SAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Company will provide a clinical update on Monday, October 30, 2023 at 8:30 AM Eastern Time, in conjunction with poster presentations at the European School of Haematology (ESH) 6th International Conference: Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment, being held October 29-31, 2023, in Estoril, Portugal. The webcast event will include a comprehensive review of up-to-date clinical data for Aptose’s lead compound tuspetinib and will feature Naval Daver, MD, Professor, Director Leukemia...